Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- President of Sawai Expects Generic Use Promotion in Next Medical Fee Revision
November 11, 2011
- Daiichi Sankyo Introduces AKT Inhibitor from US Firm, Obtains License Worldwide
November 11, 2011
- Ono to Restructure for Stronger Research Support System
November 11, 2011
- Sales of Ethical Drugs Up 5.6% in September: Crecon Report
November 11, 2011
- US FDA Accepts Filing for Astellas Pharma’s Mirabegron
November 11, 2011
- Nipro: Net Profits Down 81.5% due to Great East Japan Earthquake
November 11, 2011
- Fuso’s Ordinary and Net Losses were Pushed into Deficit by Quake (April-September 2011)
November 10, 2011
- Asahi Kasei Pharma to Accelerate Coagulant Development, Makes US Venture Wholly-Owned Subsidiary
November 10, 2011
- UCB, Otsuka to Apply for Domestic Approval of RA Drug in 2012
November 10, 2011
- Pharmaceutical Sales Up 0.5% in Bayer AG Jan-Sep Results
November 10, 2011
- Daiichi Sankyo Obtains Brazil Rights for OAB Treatment Uritos
November 10, 2011
- Nippon Shinyaku Increases Both Sales, Profits Driven by Growth of Vidaza
November 10, 2011
- Premium for New Drug Development Should Be Increased: Mr Miyoshi of IMS Japan
November 10, 2011
- Sanofi Expected to Overtake Pfizer as World’s Top Drug Maker in 2012: Evaluate Pharma
November 10, 2011
- Seikagaku to Conduct Add’l PIII Trial for Lumbar Disc Herniation Treatment SI-6603
November 10, 2011
- Toho HD’s Sales Increased to ¥2 Bil. in 1st-Half Driven by Dispensing Pharmacy Business
November 9, 2011
- Toho Holdings' Matsutani Says His Company Will Protect Its Own Prices
November 9, 2011
- Operating Profit Rate for Top-4 Wholesalers Slips to 0.39% in April-September
November 9, 2011
- Astellas, RIKEN to Explore, Jointly Develop Novel Drug Targets for AD
November 9, 2011
- Yakult, LivTech Enter into Option Agreement for Anti-Cancer Monoclonal Antibody Development Program
November 9, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…